Pinaverium Bromide Preventing Post Extracorporeal Shock Wave Lithotripsy Pancreatitis and Painful (PBPEP)

Launched by YANQING LI · Apr 17, 2025

Keywords

ClinConnect Summary

1. Background:

* Chronic pancreatitis (CP) has a global incidence of 9.62/100,000, often complicated by pancreatic duct stones (90% of CP patients).
* p-ESWL is first-line for stones \>5 mm but carries risks: pancreatitis (4.35%), abdominal pain (42.65%), and other complications (6.73% overall).
* Pinaverium bromide relaxes the sphincter of Oddi, reduce intestinal spasms and may mitigate post-ESWL complications.
2. Objectives:

* Primary: Reduce post-p-ESWL pancreatitis incidence (per Atlanta 2012 criteria).
* Secondary: Decrease abdominal pain, other complications (bleeding...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Gender is not limited, age range is 18-85 years old (inclusive);
• • 2. Perform P-ESWL treatment for painful chronic pancreatitis with positive pancreatic duct stones ≥ 5mm, mainly located in the head or body of the pancreas.
• Exclusion Criteria:
• • 1. Requiring repeat ESWL during the study period.
• • 2. Acute pancreatitis within 3 days prior to ESWL.
• • 3. Severe cardiac/pulmonary dysfunction precluding anesthesia tolerance.
• • 4. Advanced liver disease (e.g., liver failure, cirrhosis, ascites, abscess).
• • 5. Anticoagulant use within 3 days or coagulopathy.
• • 6. Suspected or confirmed pancreatic malignancy.
• • 7. Arteriosclerosis or aortic aneurysm along shockwave transmission path.
• • 8. Pregnancy or lactation.
• • 9. Known allergy to pinaverium bromide.
• • 10. Chronic pinaverium bromide use with \<3-day washout period.
• • 11. Declined participation.